[{"orgOrder":0,"company":"Imvaq Therapeutics","sponsor":"Hanne Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"MQ710","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Imvaq Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Imvaq Therapeutics \/ Hanne Capital","highestDevelopmentStatusID":"4","companyTruncated":"Imvaq Therapeutics \/ Hanne Capital"}]

Find Clinical Drug Pipeline Developments & Deals by Imvaq Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The funds will enable the company to catalyze the Phase 1 clinical development of its first therapeutic candidate MQ710, a novel 2nd-generation viral immunotherapy based on armed Modified Vaccinia Ankara (MVA), and to advance additional novel assets in i...

                          Brand Name : MQ710

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 28, 2020

                          Lead Product(s) : MQ710

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Hanne Capital

                          Deal Size : $15.0 million

                          Deal Type : Series B Financing

                          blank